Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Piretanide→

Piretanide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
55837-27-9
Molecular formula
C17H18N2O5S
Molecular weight
362.4 g/mol
Drug class
Loop diureticsulfamoylbenzoic acid derivative
Mechanism of action
Inhibits the Na-K-2Cl (NKCC2) cotransporter in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption and increasing renal excretion of sodium, chloride, potassium and water.
Indications / reported uses
  • Treatment of oedema associated with cardiac, renal or hepatic disorders and selected hypertension settings where piretanide remains authorised.

Sources: https://www.ncbi.nlm.nih.gov/books/NBK546656/ · https://www.ncbi.nlm.nih.gov/books/NBK557838/ · https://pubchem.ncbi.nlm.nih.gov/compound/4864 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Piretanide Environmental Risk Assessment (ERA) (the Piretanide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.